Bio/Pharma Business

Strategic restructuring is designed to position GE Healthcare as a pure-play healthcare company.

GW Research’s Epidiolex, which treats two forms of epilepsy, receives FDA’s approval; spurs FDA reminders about unapproved products.

The three-year collaboration will focus on developing vaccines for up to five infectious disease pathogens.

Intelligent manufacturing and environmental policies are key trends at P-MEC 2018.

The India Expo Mart in Delhi will host CPhI and P-MEC India with expected attendance of 50,000.

The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.

Allergan will buy a potential depression treatment from Aptinyx.

The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.

Internationalization and regulatory reform are driving growth and investment China.

Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.

The BioIndustry Association has called on the British government to introduce a new venture capital fund structure that will enable the public to invest in the United Kingdom’s biotech revolution.

Barriers impede biosimilar market entry into the United States despite the Biologics Price Competition and Innovation Act.

Takeda expands its global and therapy base with announced acquisition of Shire.

A skilled workforce is needed to deliver on technology’s promising medical advances.

LNC Therapeutics has appointed a new CEO and is strengthening its R&D for gut microbiome-based drugs.

The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.

Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.

Johnson & Johnson’s Janssen partners with Bristol-Myers Squibb to advance next-generation therapies for cardiovascular diseases.

The acquisition is expected to accelerate progress towards personalized cancer healthcare.

Roche has acquired a program to develop regenerative therapies for multiple sclerosis.

Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.

Boehringer Ingelheim and OSE Immunotherapeutics have entered a global immuno-oncology partnership to develop a checkpoint inhibitor for treating advanced solid tumors.

The companies have created Syna Therapeutics, a joint venture that will develop biosimilars and new molecules.

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

Pfizer transfers CAR-T assets to Allogene Therapeutics under a new alliance to further develop immuno-oncology therapeutics.

New therapies and tighter budgets challenge bio/pharma to think outside the industry.

The company’s close communication with customers has enabled it to bring advanced pipetting products to market.

The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.

The companies will co-develop and co-promote a CAR T cell therapy in the United States.

Takeda is considering approaching Shire with a possible offer.